United States securities and exchange commission logo





                          December 2, 2020

       James F. Oliviero
       Chief Executive Officer
       Checkpoint Therapeutics, Inc.
       2 Gansevoort Street, 9th Floor
       New York, NY 10014

                                                        Re: Checkpoint
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed November 27,
2020
                                                            File No. 333-251005

       Dear Mr. Oliviero:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Ada D.
Sarmento at 202-551-3798 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Mark F. McElreath, Esq.